ClinicalTrials.Veeva

Menu

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

argenx logo

argenx

Status

Enrolling

Conditions

Congenital Myasthenic Syndrome

Study type

Observational

Funder types

Industry

Identifiers

NCT06078553
ARGX-119-NIS-2301

Details and patient eligibility

About

Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7, MUSK, AGRN, or LRP4.

Enrollment

100 estimated patients

Sex

All

Ages

2+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Can understand the requirements of the study and can provide written informed consent/assent, and willingness and ability to comply with the study protocol procedures
  • Is male or female and aged ≥2 years at the time of providing informed consent/assent
  • Has a diagnosis of CMS due to biallelic pathogenic mutations in DOK7 or any pathogenic mutations in MUSK, AGRN, or LRP4
  • Has a total Quantitative Myasthenia Gravis (QMG) score of ≥3 (applies only to participants aged ≥6 years)
  • For participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine), participant must have been receiving the medication for ≥3 months before screening/baseline

Exclusion criteria

  • Known medical condition that would interfere with an accurate assessment of CMS, in the investigator's opinion
  • Is currently participating in any interventional clinical study with a study drug at the time of providing informed consent/assent
  • Diagnosis of CMS due to mutation of any gene other than DOK7, MUSK, AGRN, or LRP4

Trial contacts and locations

10

Loading...

Central trial contact

Sabine Coppieters, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems